SAB Biotherapeutics (SABS) Shares Outstanding (Diluted Average) (2020 - 2026)

SAB Biotherapeutics has reported Shares Outstanding (Diluted Average) for 7 years, with the latest figure at $53.6 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) rose 476.42% year-over-year to $53.6 million; the trailing twelve-month figure through Mar 2026 stood at $53.6 million (up 476.42% YoY), and the FY2024 full-year result was $9.3 million, up 67.74% from the prior year.
• Shares Outstanding (Diluted Average) for Q1 2026 stood at $53.6 million, down from $77.9 million in the prior quarter.
• The five-year high for Shares Outstanding (Diluted Average) was $77.9 million in Q3 2025, with the low at $4.4 million in Q4 2022.
• Historically, Shares Outstanding (Diluted Average) has averaged $21.5 million across 5 years, with a median of $9.3 million in 2024.
• Annual changes were most pronounced in 2023 — Shares Outstanding (Diluted Average) plunged 89.0% — and 2025, when it jumped 740.93%.
• SAB Biotherapeutics' Shares Outstanding (Diluted Average) stood at $4.4 million in 2022, then increased by 26.86% to $5.5 million in 2023, then soared by 67.74% to $9.3 million in 2024, then surged by 740.68% to $77.9 million in 2025, then plunged by 31.21% to $53.6 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $53.6 million (Q1 2026), $77.9 million (Q3 2025), and $9.3 million (Q2 2025), per Business Quant data.